The Relationship of glutamate signaling to cannabis use and schizophrenia

被引:0
|
作者
Niznikiewicz, Margaret [1 ,2 ]
Lin, Alexander [2 ,3 ]
Delisi, Lynn E. [2 ,4 ]
机构
[1] VA Boston Healthcare Syst, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA USA
[4] Cambridge Hlth Alliance, Cambridge, MA USA
关键词
functional magnetic resonance imaging; genetic risk; marijuana; magnetic resonance spectroscopy; the default mode network; DEFAULT MODE NETWORK; STATE FUNCTIONAL CONNECTIVITY; HUMAN BRAIN; DELTA(9)-TETRAHYDROCANNABINOL; RECEPTORS; PHARMACOLOGY; CHILDHOOD; PSYCHOSIS; COGNITION;
D O I
10.1097/YCO.0000000000001003
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of reviewThis review examines the literature associating cannabis with schizophrenia, glutamate dysregulation in schizophrenia, and cannabis involvement in glutamate pathways. Cannabis use is widespread among adolescents world-wide and is sold legally in many countries for recreational use in a variety of forms. Most people use it without lasting effects, but a portion of individuals have negative reactions that manifest in acute psychotic symptoms, and in some, symptoms continue even after the use of cannabis has ceased. To date, there is a huge gap in our understanding of why this occurs.Recent findingsRecent studies have focused on abnormalities in the glutamate pathway in schizophrenia, the effect of cannabis on the glutamate system, and the role of glutamate in the brain Default Mode Network.SummaryGiven these observations, we hypothesize that perturbance of glutamate neuronal connectivity by cannabis in the brains of individuals genetically at high risk for psychosis will initiate a schizophrenia-like psychosis. Future studies may tie together these diverse observations by combining magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI) of the default resting state network in patients with new onset schizophrenia who do and do not use cannabis compared with nonpsychotic individuals who do and do not use cannabis.
引用
收藏
页码:177 / 181
页数:5
相关论文
共 50 条
  • [41] Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales
    Hickman, Matthew
    Vickerman, Peter
    Macleod, John
    Kirkbride, James
    Jones, Peter B.
    ADDICTION, 2007, 102 (04) : 597 - 606
  • [42] The relationship of age to cannabis use and motives for use among medical cannabis dispensary patients
    Sottile, James E.
    Haug, Nancy A.
    Padula, Claudia Beatriz
    Heinz, Adrienne
    Bonn-Miller, Marcel O.
    DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E194 - E194
  • [43] Tobacco, alcohol and cannabis use in Tunisian patients with schizophrenia
    Laqueille, X.
    Ghodhbane, S.
    Nacef, F.
    Choubani, Z.
    Nehdi, M.
    Douki, S.
    Dervaux, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S388 - S389
  • [44] Cannabis use and risk of schizophrenia: Potential biological mechanisms
    Lewis, David A.
    Eggan, Stephen M.
    Hashimoto, Takanori
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 154S - 154S
  • [45] Cannabis use and risk of schizophrenia: a Mendelian randomization study
    J Vaucher
    B J Keating
    A M Lasserre
    W Gan
    D M Lyall
    J Ward
    D J Smith
    J P Pell
    N Sattar
    G Paré
    M V Holmes
    Molecular Psychiatry, 2018, 23 : 1287 - 1292
  • [46] CLINICAL FEATURES OF SCHIZOPHRENIA IN PATIENTS WITH A HISTORY OF CANNABIS USE
    Ben Mariem, H.
    Zalila, H.
    Khelifa, E.
    Ben Assi, W.
    Boussetta, A.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [47] Does cannabis use affect endogenous cannabinolds in schizophrenia?
    Leweke, FM
    Giuffrida, A
    Koethe, D
    Schreiber, D
    Gerth, CW
    Piomelli, D
    Klosterkötter, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S295 - S295
  • [48] Tobacco, alcohol and cannabis use in Tunisian patients with schizophrenia
    Laqueille, Xavier
    Ghodhbane, Souheil
    Nacef, Fethi
    Choubani, Zied
    Nehdi, Mohamed
    Douki, Saida
    Dervaux, Alain
    SCHIZOPHRENIA RESEARCH, 2008, 98 (1-3) : 327 - 328
  • [49] Inhibition of return (IOR) in patients with schizophrenia and cannabis use
    Schnell, Thomas
    Heekeren, Karsten
    Daumann, Jorg
    Gouzoulis-Mayfrank, Euphrosyne
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 89 : 65 - 72
  • [50] Prognosis of schizophrenia in persons with and without a history of cannabis use
    Manrique-Garcia, E.
    Zammit, S.
    Dalman, C.
    Hemmingsson, T.
    Andreasson, S.
    Allebeck, P.
    PSYCHOLOGICAL MEDICINE, 2014, 44 (12) : 2513 - 2521